{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:58:56Z","timestamp":1770141536584,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00280-021-04274-6","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T20:03:37Z","timestamp":1619467417000},"page":"189-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Population pharmacokinetics and exposure\u2013response of selumetinib and its N\u2010desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8204-5242","authenticated-orcid":false,"given":"Stein","family":"Schalkwijk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarit","family":"Cohen\u2010Rabbie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lokesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Freshwater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Gioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Tomkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthick","family":"Vishwanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diansong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"issue":"4","key":"4274_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/s1474-4422(07)70075-3","volume":"6","author":"RE Ferner","year":"2007","unstructured":"Ferner RE (2007) Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 6(4):340\u2013351. https:\/\/doi.org\/10.1016\/s1474-4422(07)70075-3","journal-title":"Lancet Neurol"},{"issue":"4","key":"4274_CR2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jpeds.2011.04.008","volume":"159","author":"R Nguyen","year":"2011","unstructured":"Nguyen R, Kluwe L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF (2011) Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr 159(4):652-655.e652. https:\/\/doi.org\/10.1016\/j.jpeds.2011.04.008","journal-title":"J Pediatr"},{"key":"4274_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1146\/annurev.ne.16.030193.001151","volume":"16","author":"D Viskochil","year":"1993","unstructured":"Viskochil D, White R, Cawthon R (1993) The neurofibromatosis type 1 gene. Annu Rev Neurosci 16:183\u2013205. https:\/\/doi.org\/10.1146\/annurev.ne.16.030193.001151","journal-title":"Annu Rev Neurosci"},{"issue":"8","key":"4274_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","volume":"6","author":"BR Davies","year":"2007","unstructured":"Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen activated protein kinase\/extracellular signal-regulated kinase kinase 1\/2 kinases: mechanism of action in vivo, pharmacokinetic\/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6(8):2209\u20132219. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0231","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"4274_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2012.43.0454","volume":"31","author":"PJ Roberts","year":"2013","unstructured":"Roberts PJ, Stinchcombe TE (2013) KRAS mutation: should we test for it, and does it matter? J Clin Oncol 31(8):1112\u20131121. https:\/\/doi.org\/10.1200\/JCO.2012.43.0454","journal-title":"J Clin Oncol"},{"issue":"2","key":"4274_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/pcmr.12304","volume":"28","author":"JJ Luke","year":"2015","unstructured":"Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD (2015) Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 28(2):135\u2013147. https:\/\/doi.org\/10.1111\/pcmr.12304","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"4274_CR7","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","volume":"13","author":"TC Yeh","year":"2007","unstructured":"Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K, Wallace E (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen\u2010activated protein kinase kinase 1\/2 inhibitor. Clin Cancer Res 13(5):1576\u20131583. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1150","journal-title":"Clin Cancer Res"},{"issue":"26","key":"4274_CR8","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC (2016) Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 375(26):2550\u20132560. https:\/\/doi.org\/10.1056\/NEJMoa1605943","journal-title":"N Engl J Med"},{"issue":"15","key":"4274_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC (2020) Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 382(15):1430\u20131442. https:\/\/doi.org\/10.1056\/NEJMoa1912735","journal-title":"N Engl J Med"},{"key":"4274_CR10","unstructured":"FDA Prescribing information. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/. Accessed 13 September 2016"},{"issue":"1","key":"4274_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bcp.13404","volume":"84","author":"P Patel","year":"2018","unstructured":"Patel P, Howgate E, Martin P, Carlile DJ, Aarons L, Zhou D (2018) Population pharmacokinetics of the MEK inhibitor selumetinib and its active N\u2010desmethyl metabolite: data from 10 phase I trials. Br J Clin Pharmacol 84(1):52\u201363. https:\/\/doi.org\/10.1111\/bcp.13404","journal-title":"Br J Clin Pharmacol"},{"key":"4274_CR12","doi-asserted-by":"publisher","unstructured":"Patel YT, Daryani VM, Patel P, Zhou D, Fangusaro J, Carlile DJ, Martin PD, Aarons L, Stewart CF (2017) Population pharmacokinetics of selumetinib and its metabolite N\u2010desmethyl-selumetinib in adult patients with advanced solid tumors and children with low-grade gliomas. CPT: Pharmacom Syst Pharmacol 6 (5):305\u2013314. https:\/\/doi.org\/10.1002\/psp4.12175","DOI":"10.1002\/psp4.12175"},{"issue":"1","key":"4274_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/jcph.1295","volume":"59","author":"X Tong","year":"2019","unstructured":"Tong X, Xu H, Carlile DJ, Tomkinson H, Al-Huniti N, Zhou D (2019) Population pharmacokinetic and exposure-response analysis of selumetinib and its N\u2010desmethyl metabolite in patients with non\u2010small cell lung cancer. J Clin Pharmacol 59(1):112\u2013122. https:\/\/doi.org\/10.1002\/jcph.1295","journal-title":"J Clin Pharmacol"},{"issue":"18","key":"4274_CR14","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.4155\/bio-2016-0082","volume":"8","author":"P Severin","year":"2016","unstructured":"Severin P, Bailey C, Chen M, Fisher A, Holmes V (2016) Determination of selumetinib, N\u2010desmethyl selumetinib and selumetinib amide in human biological samples by LC-MS\/MS. Bioanalysis 8(18):1919\u20131936. https:\/\/doi.org\/10.4155\/bio-2016-0082","journal-title":"Bioanalysis"},{"issue":"4","key":"4274_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1208\/s12248-011-9304-7","volume":"13","author":"D Morris","year":"2011","unstructured":"Morris D, Podolski J, Kirsch A, Wiehle R, Fleckenstein L (2011) Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. AAPS J 13(4):665\u2013673. https:\/\/doi.org\/10.1208\/s12248-011-9304-7","journal-title":"AAPS J"},{"issue":"4","key":"4274_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401\u2013421. https:\/\/doi.org\/10.1007\/s10928-008-9094-4","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"4274_CR17","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.clinthera.2017.08.022","volume":"39","author":"H Tomkinson","year":"2017","unstructured":"Tomkinson H, McBride E, Martin P, Lisbon E, Dymond A, Cantarini M, So K, Holt D (2017) Comparison of the pharmacokinetics of the phase II and phase III capsule formulations of selumetinib, and the effects of food on exposure: results from two randomised cross-over trials in healthy male subjects. Clin Ther 39(11):2260\u20132275. https:\/\/doi.org\/10.1016\/j.clinthera.2017.08.022","journal-title":"Clin Ther"},{"issue":"3","key":"4274_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN (2005) PsN\u2010Toolkit\u2013a collection of computer intensive statistical methods for non\u2010linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed 79(3):241\u2013257. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005","journal-title":"Comput Methods Prog Biomed"},{"key":"4274_CR19","doi-asserted-by":"publisher","unstructured":"Burnham KP, Anderson DR (2002) Model selection and multimodel inference: a practical information theoretic approach. 2 edn. Springer, New York. https:\/\/doi.org\/10.1007\/b97636","DOI":"10.1007\/b97636"},{"key":"4274_CR20","unstructured":"Karlsson MO, Holford N (2008) A tutorial on visual predictive checks. PAGE. www.page-meeting.org\/?abstract=1434."},{"issue":"2","key":"4274_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction\u2010corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"issue":"21 Suppl 1","key":"4274_CR22","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi E, Ardern\u2010Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC, Collaboration REI (2013) Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81(21 Suppl 1):S33-40. https:\/\/doi.org\/10.1212\/01.wnl.0000435744.57038.af","journal-title":"Neurology"},{"key":"4274_CR23","doi-asserted-by":"publisher","unstructured":"Ghadi R, Dand N (2017) BCS class IV drugs: Highly notorious candidates for formulation development. J Control Release 248:71\u201395. https:\/\/doi.org\/10.1016\/j.jconrel.2017.01.014","DOI":"10.1016\/j.jconrel.2017.01.014"},{"issue":"2","key":"4274_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/now158","volume":"19","author":"RI Jakacki","year":"2017","unstructured":"Jakacki RI, Dombi E, Steinberg SM, Goldman S, Kieran MW, Ullrich NJ, Pollack IF, Goodwin A, Manley PE, Fangusaro J, Allen R, Widemann BC (2017) Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol 19(2):289\u2013297. https:\/\/doi.org\/10.1093\/neuonc\/now158","journal-title":"Neuro Oncol"},{"issue":"6","key":"4274_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/pbc.24873","volume":"61","author":"B Weiss","year":"2014","unstructured":"Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ (2014) Sirolimus for non\u2010progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer 61(6):982\u2013986. https:\/\/doi.org\/10.1002\/pbc.24873","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"4274_CR26","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/pbc.25041","volume":"61","author":"BC Widemann","year":"2014","unstructured":"Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A, Goodspeed W, Kieran MW, Cohen B, Blaney SM, King A, Solomon J, Patronas N, Balis FM, Fox E, Steinberg SM, Packer RJ (2014) Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer 61(9):1598\u20131602. https:\/\/doi.org\/10.1002\/pbc.25041","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"4274_CR27","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","volume":"139","author":"O Zehou","year":"2019","unstructured":"Zehou O, Ferkal S, Brugieres P, Barbarot S, Bastuji-Garin S, Combemale P, Valeyrie-Allanore L, Sbidian E, Wolkenstein P (2019) Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a phase 2a trial. J Invest Dermatol 139(3):718\u2013720. https:\/\/doi.org\/10.1016\/j.jid.2018.09.016","journal-title":"J Invest Dermatol"},{"issue":"12","key":"4274_CR28","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/s1470-2045(12)70414-x","volume":"13","author":"KA Robertson","year":"2012","unstructured":"Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW (2012) Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 13(12):1218\u20131224. https:\/\/doi.org\/10.1016\/s1470-2045(12)70414-x","journal-title":"Lancet Oncol"},{"issue":"5","key":"4274_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/neuonc\/nou004","volume":"16","author":"BC Widemann","year":"2014","unstructured":"Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM (2014) Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol 16(5):707\u2013718. https:\/\/doi.org\/10.1093\/neuonc\/nou004","journal-title":"Neuro Oncol"},{"key":"4274_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-04731-2","author":"AM Gross","year":"2020","unstructured":"Gross AM, Dombi E, Widemann BC (2020) Current status of MEK inhibitors in the treatment of plexiform neurofibromas. Child\u2019s Nerv Syst ChNS Off J Int Soc Pediatric Neurosurg. https:\/\/doi.org\/10.1007\/s00381-020-04731-2","journal-title":"Child's Nerv Syst ChNS Off J Int Soc Pediatric Neurosurg"},{"key":"4274_CR31","doi-asserted-by":"publisher","unstructured":"Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM (2010) The first-in\u2010human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open label multicenter trial in patients with advanced cancer. Clin Cancer Res 16 (5):1613\u20131623. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2483","DOI":"10.1158\/1078-0432.CCR-09-2483"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04274-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04274-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T16:02:27Z","timestamp":1624809747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04274-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4274"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04274-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"27 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"SS, KS, HT, KV and DZ are employees of AstraZeneca, and own stock options\/shares. SC, IG and ZH are employees of AstraZeneca. TF and LJ are employees of Merck & Co., Inc., and owns stock options\/shares. LZ is a former employee of AstraZeneca and a current employee of Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As this is a pooled study based on existing data, ethics approvals for this study are not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this is a pooled study based on existing data, consent for this study is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}